About Acerta Pharma
Acerta Pharma is a Healthcare company based in Oss (Netherlands) founded in 2012, and was acquired by Astrazeneca in December 2015. Acerta Pharma is focused on developing haematology treatments. It operates on a Professional Services model. Acerta Pharma has raised $13 million across 1 funding round from investors including Astrazeneca, Orbimed and Frazier Healthcare Partners. Acerta Pharma offers products and services including Haematology Medicines. Its focus areas include Pharmaceuticals and Oncology. Its legal entity is Acerta Pharma B.V.
Company details
Acerta Pharma, an affiliate of AstraZeneca, is engaged in advancing scientific research to redefine care in haematology. Novel investigational agents are developed to target cancer cells directly or harness the immune system for cancer elimination. The focus is placed on addressing blood cancers with high unmet needs through an innovative pipeline. Collaboration with AstraZeneca enables the combination of extensive oncology portfolios for enhanced cancer therapies. Research and development activities are conducted at the Oss site in the Netherlands, emphasizing target identification and compound optimization.
- Headquarters Oss, Netherlands
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website acerta-pharma.com
- Social LinkedIn
- Acquired by Astrazeneca (Dec 2015)
- Legal Name Acerta Pharma B.V.
- Total Equity Funding$13M (USD)
in 1 rounds
- Latest Funding Round$13M (USD), Series B
Dec 2013
- InvestorsAstrazeneca
& 2 more
- Acquired byAstrazeneca
(Dec 2015)
Products & Services of Acerta Pharma
Acerta Pharma offers a comprehensive portfolio of products and services, including Haematology Medicines.
Medicines are developed for hematological malignancy treatments.
Funding Insights of Acerta Pharma
Acerta Pharma has successfully raised a total of $13M through 1 strategic funding round. The most recent funding activity was a Series B round of $13 million completed in December 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13M
- Total Rounds 1
- Last Round Series B — $13M
- First Round $13M
(Dec 2013)
- Investors Count 2
All 1 funding rounds of Acerta Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2013 | $13M | Series B | – | – |
3 investors in total: 3 institutional.
Investors in Acerta Pharma
Acerta Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, Orbimed and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for Acerta Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acerta Pharma
32 people are tracked at Acerta Pharma (7 in leadership, 3 in board & advisors, 22 in team).
| Name | Role | Group |
|---|---|---|
Jude Fitzgibbon | VP, Head of Discovery & Target Biology, Cambridge, United Kingdom | Leadership |
Raj Narlawar | Associate Director | Leadership |
Nico Stam | CEO & VP, Research Europe, Netherlands | Leadership |
Adeline Palisse | Associate Director, Medicinal Chemistry | Leadership |
Olaf Kinzel | Senior Director Medicinal Chemistry | Leadership |
Carsten Schultz-Fademrecht | Associate Director Medicinal Chemistry | Leadership |
Daniel Prins | Global Study Associate Director | Leadership |
Martijn Bax | Director | Board & advisors |
Anas Younes | Director | Board & advisors |
Niko Andre | Director | Board & advisors |
Mike Delpeut | Scientist | Team |
Ferdi van der Pijl | Senior Scientist | Team |
Sanne de Jong | Scientist Chemistry | Team |
Hendra Tatangsurja | Senior Statistical Analyst | Team |
Caroline van Oppen | Recruitment Manager RPO (vanuit Recruitment&co) | Team |
Renu Sorte | Global Study Manager | Team |
Gizem Berna Ateş | Global Study Manager | Team |
Lorraine Parker | Global Study Manager | Team |
Vera van Hoeven | Research Scientist Biology & Translational | Team |
Yvonne Thus | Senior Scientist | Team |
12 more people are available in the full profile.
Complete people profiles for Acerta Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Acerta Pharma
3 dated milestones of Acerta Pharma across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Acerta Pharma is founded.
- Funding First funding round of $13.0M.
- Exit Acquired by Astrazeneca.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acerta Pharma
Complete news archive for Acerta Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acerta Pharma
Acerta Pharma was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Acerta Pharma is headquartered in Oss, Netherlands. It is registered at Oss, Noord-brabant, Netherlands.
Acerta Pharma is a funded company, having raised a total of $13M across 1 funding round to date. The company's 1st funding round was a Series B of $13M, raised on Dec 2013.
Acerta Pharma, an affiliate of AstraZeneca, is engaged in advancing scientific research to redefine care in haematology. Novel investigational agents are developed to target cancer cells directly or harness the immune system for cancer elimination. The focus is placed on addressing blood cancers with high unmet needs through an innovative pipeline. Collaboration with AstraZeneca enables the combination of extensive oncology portfolios for enhanced cancer therapies. Research and development activities are conducted at the Oss site in the Netherlands, emphasizing target identification and compound optimization.
Acerta Pharma offers Haematology Medicines.
Acerta Pharma has 3 investors. Key investors include Astrazeneca, Orbimed, and Frazier Healthcare Partners.
Acerta Pharma operates through Acerta Pharma B.V..
Yes. Acerta Pharma was acquired by Astrazeneca in December 2015.